Ceftazidime-Avibactam plus Aztreonam against MBL-producing K. pneumoniae

Ceftazidime/Avibactam plus Aztreonam Synergism as Successful Treatment for Metallo-ß-lactamase-producing Multidrug-Resistant Klebsiella pneumoniae

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410744344899

Enrollment

200

Registered

2024-10-30

Start date

2022-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K. pneumoniae

Interventions

Klebsiella pneumoniae group

Healthy group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients of both sexes (male & female) and all age groups who showed signs and symptoms of infections and agreed to participate were included in this study. - Samples included were urine from catheterized and non-catheterized patients, respiratory specimens from intubated and non-intubated patients, Pus and wound swabs, pleural fluid, and blood.

Exclusion criteria

Exclusion criteria: - Patients who received antibiotic treatment in the last 48 hours or refused to participate were excluded.

Design outcomes

Primary

Measure	Time frame
Isolation and identification of K. pneumoniae	—

Secondary

Measure	Time frame
evaluated the in vitro activity of CAZ/AVI in combination with ATM against MBL-producing K. pneumoniae clinical isolates	—

Countries

Egypt

Contacts

Public ContactHasnaa Azab

Professor

hasnaa_azab@med.suez.edu.eg00201003258097

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026